PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 144 filers reported holding PROGENICS PHARMACEUTICALS IN in Q2 2019. The put-call ratio across all filers is 0.54 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $69,000 | 0.0% | 13,600 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $69,000 | -17.9% | 13,600 | 0.0% | 0.00% | -50.0% |
| Q2 2019 | $84,000 | -51.4% | 13,600 | -63.4% | 0.00% | -50.0% |
| Q1 2019 | $173,000 | +78.4% | 37,200 | +102.2% | 0.00% | +300.0% |
| Q4 2018 | $97,000 | +67.2% | 18,400 | +100.0% | 0.00% | 0.0% |
| Q3 2018 | $58,000 | – | 9,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadfin Capital, LLC | 1,583,925 | $8,007,000 | 1.48% |
| Phocas Financial Corp. | 1,022,708 | $5,169,000 | 0.55% |
| RICE HALL JAMES & ASSOCIATES, LLC | 1,776,490 | $8,980,000 | 0.32% |
| FARALLON CAPITAL MANAGEMENT LLC | 7,350,000 | $37,154,000 | 0.28% |
| NEXPOINT ASSET MANAGEMENT, L.P. | 716,880 | $3,624,000 | 0.23% |
| J. Goldman & Co LP | 499,698 | $2,526,000 | 0.19% |
| PINNACLE ASSOCIATES LTD | 1,257,098 | $6,355,000 | 0.15% |
| CARILLON TOWER ADVISERS, INC. | 3,948,024 | $19,957,000 | 0.14% |
| EAGLE ASSET MANAGEMENT INC | 4,504,094 | $22,768,000 | 0.12% |
| Worth Venture Partners, LLC | 32,956 | $167,000 | 0.10% |